Organogenesis Holdings (ORGO) Cash & Current Investments (2015 - 2026)

Organogenesis Holdings' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $92.1 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 16.68% year-over-year to $92.1 million; the TTM figure through Mar 2026 stood at $92.1 million (down 16.68% YoY), while the FY2025 annual figure was $94.3 million, down 30.72% from the prior year.
• Cash & Current Investments was $92.1 million for Q1 2026 at Organogenesis Holdings, down from $94.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $136.2 million in Q4 2024 to a low of $68.1 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $98.2 million across 5 years, with a median of $94.9 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments jumped 22080.9% in 2022, then slumped 30.72% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $103.3 million in 2022, then climbed by 1.01% to $104.3 million in 2023, then jumped by 30.49% to $136.2 million in 2024, then plunged by 30.72% to $94.3 million in 2025, then dropped by 2.37% to $92.1 million in 2026.
• The last three Cash & Current Investments figures came in at $92.1 million (Q1 2026), $94.3 million (Q4 2025), and $68.1 million (Q3 2025), per Business Quant data.